Navigation Links
ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Date:3/6/2008

- Update on Clinical Developments

MONTREAL, March 6 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces favorable top-line findings from the third cohort in its Phase II trial with PBI-1402 in patients with chemotherapy-induced anemia ("CIA"). Analysis of the compiled data from a total of 18 patients showed an overall statistically significant increase of the mean hematocrit values at weeks 4, 6 and 8, and of the hemoglobin values at week 8. At week 8, p values were 0.02 for hematocrit and hemoglobin. More detailed results from the study have been submitted to the European Hematology Association for presentation at their June 2008 meeting in Copenhagen.

"These results are very encouraging and continue to demonstrate the efficacy and safety profile of PBI-1402, a non-EPO (erythropoietin) treatment for CIA," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "We are excited about the prospects for PBI-1402 for the treatment of anemia in oncology since, unlike EPO, PBI-1402 demonstrated some anticancer activity in animal models. We look forward to sharing more detailed clinical trial results."

Other PBI-1402 development highlights include the extension of the enrollment for the PBI-1402 CIA trial to include an additional 12 patients receiving the lowest trial dose. Data from these additional patients are expected by June 2008.

In addition, a new Phase II study in patients with anemia resulting from chronic kidney disease has been scheduled. This multi-center study will be placebo controlled and will examine the effect of PBI-1402 on anemia, as well as several other clinical parameters. Conclusive results obtained recently in animal models have confirmed the erythropoiesis activity of PBI-1402 even when there is little or no endogenous EPO produced by the kidney.

About PBI-1402

PBI-1402 is an orally active compound being develo
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
2. ProMetic provides business update - Over $35 million worth of business secured in January
3. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
4. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
5. VaxGen Reports Financial Update
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
9. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/28/2014)... DIEGO, California, USA (PRWEB) August 28, 2014 ... the Department of Physics and Optical Science and Director ... the University of North Carolina at Charlotte, and co-founder ... been elected to serve as the 2015 Vice President ... , SPIE 2014 President Philip Stahl announced recent election ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... , ANNAPOLIS, Md., Aug. 13 PharmAthene, Inc. (NYSE ... against biological and chemical threats, today reported financial and operational results ... , , For the second quarter of 2009, ... the same period of 2008. For the six months ended ...
... , , , ... MON ) R&D pipeline is on the verge of a technology ... for growers and has the company poised to meet its goals ... and president, will tell investors today. , , ...
... ... , ... (PRWEB) August 13, 2009 -- Inc. magazine announced on Wednesday its 2009 Inc. 5000 ... technology solutions company and a leader in web-database solutions, healthcare intelligence and specialized job ...
Cached Biology Technology:PharmAthene Reports Second Quarter 2009 Financial and Operational Results 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 8Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7Massachusetts Technology Corporation Named to Inc. 5000 List of Fastest Growing Private Companies 2
(Date:8/28/2014)... identified a handful of bacterial culprits that may drive ... ulcerative colitis, using patients, own intestinal immune responses as ... in the journal Cell . , Trillions of ... a critical role in the development and progression of ... of bacterial species affect a person,s susceptibility to IBD ...
(Date:8/28/2014)... The zebrafish, a ... pattern of blue stripes alternating with golden stripes. Three major ... cells emerge during growth in the skin of the tiny ... the characteristic colour pattern. ,While it was known ... proper stripes, the embryonic origin of the pigment cells that ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... NY, September 4, 2012The use of RNA in nanotechnology ... development of new therapeutic compounds. Key technical challenges remain, ... use of RNA molecules in nanotechnology approaches are presented ... , a peer-reviewed journal from Mary Ann Liebert, ...
... appliances in Spain are processed out of the Integrated ... of Salamanca exposes how many manufacturers are not registered ... According to the European directive on waste electrical ... the waste they generate during their activity until reaching ...
... fungal species, called , Hebelomagriseopruinatum , has now officially ... whose name can be translated into ,the grey-dewy tear ... mushroom-hunting tour headed by postdoc Jacob Heilman-Clausen from the ... 2009, postdoc Jacob Heilman-Clausen from the Center for Macroecology, ...
Cached Biology News:More than 70% of electronic waste management is uncontrolled 2More than 70% of electronic waste management is uncontrolled 3New Danish fungal species discovered 2
... dedicated imaging system for fluorescent light due ... very sensitive camera to detect low level ... research, infectious disease research, gene expression, circadian ... the only imager with a motor-driven camera ...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
... Mouse polyclonal antibody raised ... Immunogen: ... 646 a.a) partial recombinant protein ... Accession Number: NM_006842 ...
Mouse monoclonal antibody to UGT2B10 - UDP glucuronosyltransferase 2 family, polypeptide B10...
Biology Products: